Canadian Pharmacogenomics Network for Drug Safety (CPNDS), Canada

Registration Status: Completed

Objective: Biological specimens collected for the purposes of genomic analysis of medication outcomes.

Registered Biobank Name Canadian Pharmacogenomics Network for Drug Safety (CPNDS)
Biobank Leader Dr. Bruce Carleton
Country Canada
Email for biobank inquiries
Principal Investigator Dr. Bruce Carleton
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected: